Skip to content
10-Q

Quarterly Report

APELLIS PHARMACEUTICALS, INC.

0000950170-24-088938

← back to feed
Filed
Aug 1, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Jul 25, 2024 121.77M sh
Current Liabilities Q2 2024 · Jun 30, 2024 $169.17M
Current Liabilities Q2 2024 · Dec 31, 2023 $247.59M
Total Liabilities Q2 2024 · Jun 30, 2024 $640.16M
Total Liabilities Q2 2024 · Dec 31, 2023 $594.21M
Current Assets Q2 2024 · Jun 30, 2024 $859.97M
Current Assets Q2 2024 · Dec 31, 2023 $766.33M
Total Assets Q2 2024 · Jun 30, 2024 $904.48M
Total Assets Q2 2024 · Dec 31, 2023 $788.73M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $351.19M
Cash And Equivalents Q2 2024 · Jun 30, 2023 $616.26M
Shares Diluted restated Q2 2024 · Jun 30, 2023 119.32M sh
Shares Diluted restated Q2 2024 · Jun 30, 2023 116.59M sh
Capex Q2 2024 · Jun 30, 2023 $631K
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$327.78M
Stockholders Equity Q2 2024 · Jun 30, 2023 $345.4M
Stockholders Equity Q2 2024 · Mar 31, 2023 $412.12M
Stockholders Equity Q2 2024 · Dec 31, 2022 $169.87M
Eps Diluted Q2 2024 · Jun 30, 2023 −$1.02
Eps Diluted Q2 2024 · Jun 30, 2023 −$2.57
Eps Basic Q2 2024 · Jun 30, 2023 −$1.02
Eps Basic Q2 2024 · Jun 30, 2023 −$2.57
Sga Expense Q2 2024 · Jun 30, 2023 $111.37M
Sga Expense Q2 2024 · Jun 30, 2023 $213.47M
Rd Expense Q2 2024 · Jun 30, 2023 $95.66M
Rd Expense Q2 2024 · Jun 30, 2023 $205.68M
Net Income Q2 2024 · Jun 30, 2023 −$122.04M
Net Income Q2 2024 · Jun 30, 2023 −$299.82M
Net Income Q2 2024 · Mar 31, 2023 −$177.78M
Operating Income Q2 2024 · Jun 30, 2023 −$120.44M
Operating Income Q2 2024 · Jun 30, 2023 −$295.52M
Revenue Q2 2024 · Jun 30, 2023 $94.97M
Revenue Q2 2024 · Jun 30, 2023 $139.81M